findmyKOL

Mark Gotfried, MD

Enriched profile

Pulmonologist (Pulmonary Medicine and Sleep Medicine), Pulmonary Associates, Phoenix, AZ · HonorHealth

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Phoenix, AZ · West · United StatesSpecialtyPulmonary DiseaseFocusChronic Obstructive Pulmonary Disease (COPD) Research+4
Active KOLfindmyKOL type: EliteLatest publication2024Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Mark Gotfried is Pulmonologist (Pulmonary Medicine and Sleep Medicine), Pulmonary Associates, Phoenix, AZ at HonorHealth. OpenAlex indexes 122 publications with 5,389 citations (h-index 40); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.

Data verified 11 Oct 2026

Overview

Updated 14 Oct 2026

Mark Gotfried, MD, is Pulmonologist (Pulmonary Medicine and Sleep Medicine), Pulmonary Associates, Phoenix, AZ at HonorHealth (medical staff member). The public record shows 122 publications with 5,389 citations (h-index 40), centered on Chronic Obstructive Pulmonary Disease (COPD) Research, Antibiotics Pharmacokinetics and Efficacy, Pneumonia and Respiratory Infections. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 3 companies.

  • Most recent indexed publication: 2024 · Drugs & aging
  • Top research focus: Chronic Obstructive Pulmonary Disease (COPD) Research
  • 8 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 3 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
COPD4 trialsEmphysema3 trialsPulmonary Emphysema2 trialsLung Diseases2 trialsTics1 trialAsthma

Research focus

OpenAlex concept fingerprint
Chronic Obstructive Pulmonary Disease (COPD) ResearchAntibiotics Pharmacokinetics and EfficacyPneumonia and Respiratory InfectionsInhalation and Respiratory Drug DeliveryAsthma and respiratory diseases

Drugs & molecules

across trials, industry payments and publications
Quviviqgeneric · DaridorexantClinical trials—Industry payments79Publications—Fluticasone Furoate; Umeclidinium Bromide; Vilanterol TrifenatateClinical trials—Industry payments14Publications—Nucalageneric · MepolizumabClinical trials—Industry payments6Publications—UmeclidiniumClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Idorsia Pharmaceuticals Us IncClinical trials—Industry payments79GlaxoSmithKline, LLC.Clinical trials—Industry payments30ZOLL Respicardia, Inc.Clinical trials—Industry payments6Aeris TherapeuticsClinical trials3Industry payments—AstraZenecaClinical trials1Industry payments—Keith A. RodvoldClinical trials1Industry payments—Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Clinical trials1Industry payments—University of Illinois at ChicagoClinical trials1Industry payments—WockhardtClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
122publications

Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.

5,389citations

Total citations across indexed works.

40h-index

Hirsch index (OpenAlex). i10-index 68.

Clinical & industry

trials, payments and federal funding
8clinical trials

Investigator role on registered studies.

View trials ↓
3companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2021)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    100%
    beta2-Adrenergic Agonist40%
    Albuterol Sulfate Hfa100%
    Part D<11 patients
    Corticosteroid30%
    Trelegy Ellipta100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B), 20200% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Keith A. Rodvold26Christian C. Witt13Franz Stanzel13Steven Kesten13Jim John Egan13Arschang Valipour12Felix J.F. Herth12Armin Ernst11Gerard J. Criner11Larry H. Danziger11Russell P. Rosenberg10Gregory I. Snell10Manfred Wagner10Peter Mark-Anthony Hopkins9Gary K Zammit9Kim Baker9Kingman Perkins Strohl8Mark T. Dransfield8Atul Malhotra7Paula Klingenberg Schweitzer7William M. Leeds7Jed E. Black6Thomas R. Gildea5Geoffrey McLennan5Charlie Strange4Michael Denenberg4Ronald J. Servi4George L. Drusano4Neil A. Ettinger4Mark J. Krasna4Surya Prakash Bhatt4Kevin W. Garey4Michael M. Kitt4Geert Mayer3Danielle E Antin-Ozerkis3Rakesh Chugh3Daniela Gompelmann3Mary Beth Scholand3Ganesh Raghu3MeiLan King Han3

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Editorial Board Member (Pulmonary)

    Southwest Journal of Pulmonary and Critical Care

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →swjpcc.com ↗

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.